Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 1, 2015, Pages 28-35

  Abi Aad, Simon ^a   Pierce, Matthew ^a   Barmaimon, Guido ^a   Farhat, Fadi S ^b   Benjo, Alexandre ^a   Mouhayar, Elie ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b LEBANESE UNIVERSITY   (Lebanon)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Hypertension; Review

Indexed keywords

ALKYLATING AGENT; AMLODIPINE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCINEURIN INHIBITOR; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; ISRADIPINE; LOSARTAN; METHOTREXATE; MINERALOCORTICOID ANTAGONIST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; RECOMBINANT ERYTHROPOIETIN; STEROID; SUNITINIB; TACROLIMUS; VASCULOTROPIN INHIBITOR;

ANEMIA; ANGINA PECTORIS; ANTIANGIOGENIC THERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CARDIOTOXICITY; COMORBIDITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; GOUT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY CARCINOMA; LEUKEMIA; LOW DRUG DOSE; NEPHROTOXICITY; PATIENT MONITORING; PREVALENCE; REVIEW; SOLID TUMOR; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS;

EID: 84915751159     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.08.004     Document Type: Review

References (67)

1. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
2. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
3. Snider K.L., Maitland M.L. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009, 4:67-76.
4. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
5. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. American Society of Hypertension 18th Annual Scientific Session 2003.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
7. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
8. Wijermans P.W., Lubbert M., Verhoef G., Klimek V., Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 84(Suppl. 1):9-17.
9. Whitworth J.A., Mangos G.J., Kelly J.J. Cushing, cortisol, and cardiovascular disease. Hypertension 2000, 36:912-916.
10. Klabunde R.E. Cardiovascular physiology concepts 2005, Lippincott Williams & Wilkins.
11. Oparil S., Zaman M.A., Calhoun D.A. Pathogenesis of hypertension. Ann Intern Med 2003, 139:761-776.
12. Calhoun D.A.Z.A., Oparil S. Etiology and pathogenesis of systemic hypertension. Cardiology 2003, 463-471. Mosby, Philadelphia. 2nd ed. M.H. Crawford, J.P. DiMarco, W.J. Paulus (Eds.).
13. Ganetsky M., Babu K.M., Salhanick S.D., Brown R.S., Boyer E.W. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011, 7:281-287.
14. Maitland M.L., Bakris G.L., Black H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010, 102:596-604.
15. Jain M., Townsend R.R. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007, 9:320-328.
16. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
17. Jain R. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008, 8:309-316.
18. Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
19. Grossman E., Messerli F.H. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 2008, 10:556-566.
20. Copur M.S., Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011, 10:151-156.
21. Nazer B., Humphreys B.D., Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011, 124:1687-1691.
22. Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012, 125:14-22.
23. Izzedine H., Ederhy S., Goldwasser F., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2009, 20:807-815.
24. Syrigos K.N., Karapanagiotou E., Boura P., Manegold C., Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011, 25:159-169.
25. Graves S.W., Eder J.P., Schryber S.M., et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (Lond) 1989, 77:501-507.
26. Berliner S., Rahima M., Sidi Y., et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990, 8:583-586.
27. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18:1725-1732.
28. Drugge R.J., Handschumacher R.E. Cyclosporine-mechanism of action. Transplant Proc 1988, 20:301-309.
29. Morales J.M., Andres A., Rengel M., Rodicio J.L. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001, 16(Suppl. 1):121-124.
30. Deray G., Benhmida M., Le Hoang P., et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992, 117:578-583.
31. Ponticelli C., Montagnino G., Aroldi A., Angelini C., Braga M., Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis 1993, 21:73-78.
32. Loughran T.P., Deeg H.J., Dahlberg S., Kennedy M.S., Storb R., Thomas E.D. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol 1985, 59:547-553.
33. Cifkova R., Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001, 19:2283-2285.
34. Rodicio J.L. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000, 35:S7-S11.
35. Chen Y.H., Liang Y.X., Chen L.Q., et al. Nephrotoxicity of tacrolimus and preventive effect of diltiazem: experiment with rats. Zhonghua Yi Xue Za Zhi 2009, 89:704-708.
36. Bursztyn M., Zelig O., Or R., Nagler A. Isradipine for the prevention of cyclosporine-induced hpertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. Transplantation 1997, 63:1034-1036.
37. McCauley J., Fung J., Jain A., Todo S., Starzl T.E. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990, 22:17-20.
38. Jain A., Reyes J., Kashyap R., et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999, 230:441-448. discussion 8-9.
39. Pham S.M., Kormos R.L., Hattler B.G., et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996, 111:764-772.
40. Ruiz-Ortega M., Esteban V., Ruperez M., et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006, 15:159-166.
41. Mourad G., Ribstein J., Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993, 43:419-425.
42. Curtis J.J., Laskow D.A., Jones P.A., Julian B.A., Gaston R.S., Luke R.G. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993, 3:1570-1574.
43. Ahmad T., Coulthard M.G., Eastham E.J. Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin. Nephrol Dial Transplant 1989, 4:311-312.
44. Schmidt A., Gruber U., Bohmig G., Koller E., Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001, 16:1034-1037.
45. Schwarzbeck A., Wittenmeier K.W., Hallfritzsch U. Anaphylactoid reactions, angiotensin-converting enzyme inhibitors and extracorporeal hemotherapy. Nephron 1993, 65:499-500.
46. Tripathi M., Kaushik S., Gaur A., Kher V. Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study. J Indian Med Assoc 1997, 95:543-545. 7.
47. West C., Carpenter B.J., Hakala T.R. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1987, 10:369-372.
48. Hoes A.W., Grobbee D.E., Peet T.M., Lubsen J. Do non-potassium-sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence. Drugs 1994, 47:711-733.
49. Wolff D., Steiner B., Hildebrandt G., Edinger M., Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des 2009, 15:1974-1997.
50. Fujihara C.K., Noronha I.L., Malheiros Antunes G.R., de Oliveira I.B., Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000, 11:283-290.
51. Grossman E.M.F. Management of drug-induced and iatrogenic hypertension. Hypertension primer 2003, 516-519. Lippincott Williams & Wilkins, Dallas, TX. 3rd ed.
52. Funder J. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997, 885-899.
53. Whitworth J.A. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992, 37:S34-S37.
54. Brem A.S. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001, 37:1-10.
55. Bernal-Mizrachi C., Weng S., Feng C., et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 2003, 9:1069-1075.
56. Whitworth J.A., Kelly J.J., Brown M.A., Williamson P.M., Lawson J.A. Glucocorticoids and hypertension in man. Clin Exp Hypertens 1997, 19:871-884.
57. Min D.I., Monaco A.P. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991, 11:119S-125S.
58. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004, 40:2201-2216.
59. Smith K.J., Bleyer A.J., Little W.C., Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003, 59:538-548.
60. Vaziri N.D. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999, 33:821-828.
61. Novak B.L., Force R.W., Mumford B.T., Solbrig R.M. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy 2003, 23:265-269.
62. Luft F.C. Erythropoietin and arterial hypertension. Clin Nephrol 2000, 53:S61-S64.
63. Mourad J.J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by Bevacizumab. A crucial role for microcirculation. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2008, 19:927-934.
64. Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009, 54:652-658.
65. Vaklavas C., Lenihan D., Kurzrock R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target. Oncologist 2010, 15:130-141.
66. Doll D.C., List A.F., Greco F.A., Hainsworth J.D., Hande K.R., Johnson D.H. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986, 105:48-51.
67. Daher I.N., Yeh E.T. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008, 5:797-805.